Form 8-K - Current report:
SEC Accession No. 0001178913-25-000836
Filing Date
2025-03-14
Accepted
2025-03-14 06:59:46
Documents
15
Period of Report
2025-03-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2532868.htm   iXBRL 8-K 52135
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 32764
  Complete submission text file 0001178913-25-000836.txt   275020

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250314.xsd EX-101.SCH 4740
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250314_def.xml EX-101.DEF 18263
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250314_lab.xml EX-101.LAB 27748
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250314_pre.xml EX-101.PRE 20505
18 EXTRACTED XBRL INSTANCE DOCUMENT zk2532868_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)